PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases

PolyActiva and RareSight Inc. have announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments. The research collaboration agreement, leveraging…

Continue ReadingPolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases

PolyActiva presents advancements in next-generation ocular micro-implant technology at Eyecelerator @ AAO 2025

PolyActiva's Chief Scientific Officer, Michael Brubaker, Ph.D., will present a corporate overview of the company's proprietary PREZIA™ drug delivery platform at Eyecelerator @ the American Academy of Ophthalmology (AAO) 2025…

Continue ReadingPolyActiva presents advancements in next-generation ocular micro-implant technology at Eyecelerator @ AAO 2025

PolyActiva expands Executive Team to drive transformational growth and advance late-stage clinical development in the US

PolyActiva has expanded their Executive Team, appointing Wes Brazell as Chief Financial Officer, and Michael Brubaker, PhD, as Chief Scientific Officer. Their appointments come at an important time for the…

Continue ReadingPolyActiva expands Executive Team to drive transformational growth and advance late-stage clinical development in the US